TAG1 Inc. to Showcase Lead-212 Innovation at Jones Las Vegas Technology Conference

Radiopharmaceutical company TAG1 Inc. is set to participate in the upcoming Jones Las Vegas Technology and Innovation Conference, bringing its groundbreaking Lead-212 isotope technology to the forefront of medical innovation. The conference, scheduled for April 8-9, 2025, at The Venetian Resort in Las Vegas, will provide TAG1 with a strategic opportunity to highlight its advancements in targeted alpha therapies (TATs).

CEO Sumit Verma will be a featured panelist in a session titled "Radiopharma Isotope Roadmap: Clinical & Logistical Considerations," sharing the stage with executives from Lantheus Holdings and Radiopharm Theranostics. The panel represents a significant moment for the radiopharmaceutical industry, offering insights into the evolving landscape of medical isotope production and application.

The conference serves as a critical networking platform, enabling TAG1 to engage directly with institutional investors and industry professionals. Through one-on-one meetings, a virtual company presentation, and the expert panel, TAG1 aims to demonstrate its potential to transform cancer treatment by improving isotope supply chains.

Lead-212, TAG1's primary focus, represents a promising advancement in targeted alpha therapies. By providing high-purity medical isotopes, the company supports the development of innovative radioligand therapies that could potentially offer more precise and effective cancer treatments.

The event's significance extends beyond TAG1's immediate business objectives. It represents a broader conversation about technological innovations in healthcare, particularly in the complex and rapidly evolving field of radiopharmaceuticals. The conference brings together thought leaders who are actively shaping the future of medical treatments and diagnostic technologies.

With keynote addresses from notable figures like Dr. Charity Dean and Eric F. Trump, the conference promises to be a comprehensive exploration of cutting-edge healthcare and technology innovations. TAG1's participation underscores the company's commitment to advancing medical science and addressing critical challenges in cancer treatment.